US IPO Window Reopens: From AI Chips to Precision Medicine-New Listings Guide

The US IPO market is springing back to life as geopolitical tensions ease. Last Friday (April 17), precision proteomics leader $Alamar Biosciences(ALMR)$ surged over 34% on its Nasdaq debut, while emergency medical giant GMR Solutions (GMRS) officially filed its prospectus. This week, AI chip unicorn Cerebras (CBRS), mobile ad platform Liftoff Mobile (LFTO), and neuro-rehab device maker Mobia Medical (MOBI) joined or rejoined the pipeline. Here is a comprehensive breakdown of what each company does, its financials, and its investment potential.

Friday’s Benchmark: Alamar Biosciences (ALMR)

Alamar priced its IPO at $17 per share and opened at $22.91, delivering a 34% first-day pop and closing with a market cap of approximately $1.43 billion. The company upsized its offering to 11.25 million shares, raising $191 million in total proceeds.

What it does: Alamar develops the proprietary NULISA platform, enabling ultra-sensitive detection of protein biomarkers in blood for early disease screening—particularly in Alzheimer’s and Parkinson’s research.

Financials & Valuation: Revenue nearly tripled to $74.2 million in 2025 (up 195% YoY), while the net loss narrowed to $29.8 million from $47.1 million in 2024. At its current valuation, Alamar trades at roughly 19x trailing P/S, reflecting a clear market premium for early-detection proteomics technology.

The Four New Filers: At a Glance

1. Cerebras Systems (CBRS) — The $23B "Nvidia Challenger"

Cerebras publicly refiled its S-1 on April 17 after withdrawing its 2024 application due to CFIUS review. It targets a Nasdaq listing in May 2026.

What it does: Cerebras builds the Wafer Scale Engine (WSE-3), a processor that spans an entire 300mm silicon wafer. With 4 trillion transistors and 900,000 cores, it is physically 56x larger than Nvidia’s H100 and claims 21x performance at one-third the cost for certain AI workloads.

Financials & Valuation: The company generated $510 million in revenue in 2025 (+76% YoY), turning to a GAAP net income of $87.9 million (though it still posted a non-GAAP net loss of $75.7 million). After a $1 billion Series H in February, its valuation stands at $23 billion, with the IPO targeting roughly $2 billion in proceeds led by Morgan Stanley.

The OpenAI Contract: On April 16—one day before the IPO filing—OpenAI committed to a multi-year compute deal reportedly worth more than $10 billion, covering up to 750 megawatts of AI processing power through 2028. Some reports value the three-year agreement at over $20 billion. This fundamentally reshapes Cerebras’s customer-concentration risk: UAE-based G42 fell from 87% of revenue in H1 2024 to just 24% in 2025.

Investment Angle: Cerebras would be the first pure-play, non-Nvidia AI chipmaker to hit public markets in this infrastructure cycle. However, at $23 billion, it trades at roughly 45x trailing sales. The bull case depends on flawless execution of the OpenAI contract and successful diversification beyond Middle Eastern clients.

2. GMR Solutions (GMRS) — A $5.7B Revenue Defensive Play

GMR filed on Friday for a NYSE listing, targeting up to $1 billion in proceeds.

What it does: Formed in 2018 from the merger of Air Medical Group Holdings and American Medical Response, GMR is the leading US provider of emergency medical services (EMS) and alternate-site care. It operates air and ground ambulance networks, serving as a critical entry point into the healthcare system across urban and rural communities.

Financials: The company booked $5.74 billion in revenue for 2025 with a net profit of $206.2 million , making it the largest revenue generator among this cohort by a wide margin.

Investment Angle: Unlike the high-growth, high-burn tech names, GMR offers a defensive, infrastructure-like exposure to US healthcare. Its profitability and recession-resistant demand profile may attract institutional capital seeking stability amid macro uncertainty.

3. Liftoff Mobile (LFTO) — AI Advertising at 1.4B Daily Users

Liftoff refiled its IPO just two months after withdrawing in February, demonstrating management’s urgency to capitalize on the reopened window.

What it does: Formed from the 2021 merger of Liftoff and Vungle (both Blackstone-owned), the company provides AI-powered user acquisition and ad monetization software for mobile apps. Its SDK is integrated into over 140,000 apps, reaching approximately 1.4 billion daily active users and serving 1,000+ marketers globally.

Financials: Revenue reached $686 million in 2025, with core advertising revenue growing 43% YoY in the nine months ended September 30, 2025. The company significantly narrowed its net loss to $23.1 million (from $48.2 million in the prior year). It now seeks to raise up to $762 million at a valuation of up to $5.17 billion.

Investment Angle: Liftoff is a direct peer to $AppLovin Corporation(APP)$ in the AI-driven mobile ad space. The 1.4B user reach provides a formidable data moat, but investors should benchmark its pricing against AppLovin’s current multiples and monitor privacy-policy headwinds.

😍 Been eyeing Tiger merch but short on Tiger Coins? Now's your chance.

🎁 We’ve selected 4 high-demand items across practial, lifestyle, and learning, now with a lower redemption threshold!

Hot Merch Returns · Up to 43% Off

4. Mobia Medical (MOBI) — The "Small but Moated" Neuro-Rehab Play

Mobia filed on April 17 for a Nasdaq listing, targeting $100 million.

What it does: Mobia’s flagship product, Vivistim, is the first and only FDA-approved Paired Vagus Nerve Stimulation (PaVNS) system for chronic ischemic stroke survivors with moderate-to-severe upper limb impairment. The implantable device stimulates the vagus nerve during rehabilitation to enhance neuroplasticity.

Financials: Revenue doubled to $32 million in 2025 (from $15.6 million in 2024). Management estimates a $30 billion addressable market in the US, with roughly 1 million of the 4 million chronic stroke survivors eligible for therapy.

Investment Angle: Mobia is a classic high-growth medtech story: FDA exclusivity, 105% revenue growth, and an unmet clinical need. Like Alamar, it commands a scarcity premium. The IPO is led by BofA Securities, J.P. Morgan, and Goldman Sachs.

Market Signal: IPOs as M&A Currency

On the same day it listed (April 17), digital asset financial services firm Diginex announced a $1.5 billion all-stock acquisition of AI customer-intelligence firm Resulticks (2025 revenue ~$150 million). This underscores a broader trend: newly public companies are immediately leveraging their stock currency to buy AI/data capabilities. For IPO investors, this means the post-listing growth story may include aggressive M&A-driven expansion into enterprise AI agents.

Investor Strategy: How to Play This Wave

For IPO Flippers: Alamar’s 34% debut proves that medtech with FDA exclusivity or platform scarcity (NULISA, Vivistim) commands immediate demand. Mobia, with 105% growth and sole FDA approval in its niche, is the closest comp.

For Growth Investors: Cerebras is the headline act. At $23 billion, the market is pricing in near-perfect execution of the OpenAI contract. Watch for two signals post-IPO: (1) the pace at which non-G42 revenue scales, and (2) whether gross margins expand as wafer-scale production ramps.

For Defensive Allocators: GMR Solutions offers a rare combination of scale ($5.7B revenue), profitability ($206M net income), and non-cyclical demand. It is the only "infrastructure-grade" name in this cohort.

For Ad-Tech Speculators: Liftoff’s 1.4B DAU footprint and 43% core revenue growth are compelling, but its valuation (up to $5.17B, or ~7.5x sales) requires a continued bull market in mobile app spending to sustain.

Bottom Line

This week’s IPO pipeline sends a clear signal: the market is willing to pay steep premiums for AI infrastructure (Cerebras) and precision medicine (Alamar, Mobia), while also making room for profitable infrastructure (GMR) and scaled ad-tech (Liftoff). The window is open—but as Alamar’s 34% pop and Cerebras’s $23 billion valuation show, the bar for execution has never been higher. Choose your exposure based on risk tolerance, not just headline hype.